Bulk Price Of (R)-5-Hydroxymethyl Tolterodine 2026: Market Analysis & Procurement Guide
- Market Forecast: 2026 pricing is driven by raw material availability and chiral synthesis complexity.
- Quality Standards: Industrial purity requires strict control of enantiomeric excess and residual solvents.
- Procurement: Secure supply chains with verified COA documentation from established global manufacturers.
The pharmaceutical intermediate market is evolving rapidly, with specific demand surging for chiral compounds used in the synthesis of active pharmaceutical ingredients (APIs). Among these, the bulk price of key metabolites remains a critical metric for procurement managers and process chemists planning for the 2026 fiscal year. (R)-5-Hydroxymethyl Tolterodine, identified by CAS 207679-81-0, serves as a vital precursor in the manufacturing of Fesoterodine, a medication used for overactive bladder. Understanding the cost drivers and technical specifications for this molecule is essential for maintaining supply chain stability and ensuring regulatory compliance.
Current Market Pricing Trends for (R)-5-Hydroxymethyl Tolterodine in Bulk
Forecasting the bulk price for 2026 requires an analysis of upstream raw material costs and the complexity of the stereoselective synthesis involved. The molecular formula C22H31NO2 indicates a structure that requires precise chemical manipulation to maintain the (R)-configuration at the chiral center. Market data suggests that prices for high-purity chiral intermediates are subject to volatility based on the availability of starting materials such as substituted phenols and diisopropylamine derivatives.
Furthermore, regulatory pressures regarding environmental waste and solvent recovery have impacted manufacturing overheads. Facilities that invest in green chemistry protocols often command a premium, but they offer long-term stability in supply. For buyers securing large metric ton quantities, the price per kilogram typically decreases significantly compared to gram-scale research purchases. However, the cost of achieving high enantiomeric excess (ee%) remains a fixed premium due to the specialized chromatography or crystallization steps required.
Factors Influencing Industrial-Scale Procurement Costs
Several technical factors directly influence the final invoice cost when sourcing this intermediate. Procurement teams must evaluate these variables against their specific formulation needs:
- Synthesis Route Complexity: The synthesis route chosen by the manufacturer dictates the yield and purity profile. Routes that avoid expensive chiral catalysts may lower costs but risk lower optical purity.
- Industrial Purity Standards: Achieving >98.5% industrial purity via HPLC requires rigorous downstream processing. Impurities related to the S-enantiomer must be minimized to meet pharmacopeial standards.
- Packaging and Storage: Given the storage temperature requirement of -20°C to maintain stability, cold-chain logistics add to the landed cost of the material.
- Regulatory Documentation: The provision of a comprehensive COA (Certificate of Analysis) including residual solvent data and heavy metal testing is standard for GMP-grade facilities.
Manufacturers capable of scaling these processes without compromising quality are rare. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. focuses on optimizing these production parameters to offer competitive pricing while adhering to strict quality control measures. This balance is crucial for clients aiming to reduce their Cost of Goods Sold (COGS) without risking batch failures during API synthesis.
Technical Specifications and Quality Control
For process chemists, the physical and chemical properties of the intermediate are as important as the price. The molecular weight of 341.49 g/mol and the specific stereochemistry define its reactivity in subsequent coupling reactions. Below is a summary of the critical technical data required for vendor qualification:
| Parameter | Specification |
|---|---|
| Chemical Name | (R)-5-Hydroxymethyl Tolterodine |
| CAS Number | 207679-81-0 |
| Molecular Formula | C22H31NO2 |
| Molecular Weight | 341.49 g/mol |
| Purity (HPLC) | ≥ 98.5% (Typical) |
| Enantiomeric Excess | ≥ 99.0% ee |
| Appearance | Off-white to White Solid |
| Storage Conditions | -20°C, Protected from Light |
When evaluating suppliers, it is imperative to request sample batches for in-house validation. The consistency of the crystalline form can impact flowability during large-scale processing. Additionally, buyers should verify that the supplier has robust methods for detecting related substances, such as des-isopropyl impurities or oxidation byproducts. When sourcing high-purity (R)-5-Hydroxymethyl Tolterodine, buyers should ensure the vendor provides stability data under various stress conditions to guarantee shelf-life integrity during transport and storage.
How to Request a Custom Quote from GMP-Certified Manufacturers
Securing the best value for 2026 involves proactive engagement with manufacturers. Spot pricing is rarely available for multi-kilogram orders; instead, contracts are negotiated based on projected annual consumption. Procurement officers should prepare a Request for Quotation (RFQ) that specifies the required quantity, desired purity grade, and packaging preferences.
It is also advisable to audit the manufacturer's quality management system. A reliable partner will provide full transparency regarding their synthesis capabilities and supply chain security. NINGBO INNO PHARMCHEM CO.,LTD. maintains a robust framework for custom synthesis and bulk supply, ensuring that clients receive materials that align with their regulatory filings. By establishing a long-term partnership, buyers can lock in pricing structures that mitigate market fluctuations.
Conclusion
The market for (R)-5-Hydroxymethyl Tolterodine is poised for steady growth as demand for urological treatments expands globally. While price is a significant factor, the technical capability of the supplier to deliver consistent chiral purity is paramount. By focusing on verified global manufacturer partners and understanding the underlying synthesis route complexities, pharmaceutical companies can secure a reliable supply chain for 2026 and beyond. Prioritizing industrial purity and comprehensive documentation ensures that downstream API production remains efficient and compliant.